Bulletin
Investor Alert

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Deciphera Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Feb 3, 2023, 5:41 p.m.

DCPH
/zigman2/quotes/203556943/composite

$

17.00

Change

-0.03 -0.18%

Volume

Volume 15,717

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Previous close

$ 17.55

$ 17.03

Change

-0.52 -2.96%

Day low

Day high

$17.00

$17.65

Open

52 week low

52 week high

$6.51

$22.76

Open

Company Description

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastr...

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Valuation

Price to Sales Ratio

5.90

Price to Book Ratio

1.88

Enterprise Value to EBITDA

-3.48

Enterprise Value to Sales

7.64

Efficiency

Total Asset Turnover

0.18

Liquidity

Current Ratio

3.50

Quick Ratio

3.36

Cash Ratio

2.95

Profitability

Gross Margin

90.23

Operating Margin

-284.85

Pretax Margin

-311.98

Net Margin

-311.98

Return on Assets

-55.97

Return on Equity

-70.71

Return on Total Capital

-60.16

Capital Structure

Total Debt to Total Assets

7.19

Officers and Executives

Name Age Officer Since Title
Mr. Steven L. Hoerter 50 - President, Director & Chief Executive Officer
Mr. Thomas P. Kelly 50 2015 Chief Financial Officer
Dr. Matthew L. Sherman 64 2019 Chief Medical Officer & Executive Vice President
Dr. Rodrigo Ruiz Soto - 2017 Senior Vice President-Clinical Development
Dr. Daniel L. Flynn 66 - President, Chief Executive Officer & Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/17/2023 Daniel L. Flynn
Chief Scientific Officer 		2,403   Disposition at $21.24 per share. 51,039
01/17/2023 Matthew L. Sherman
EVP & Chief Medical Officer 		2,403   Disposition at $21.24 per share. 51,039
01/17/2023 Daniel C. Martin
Chief Commercial Officer 		1,603   Disposition at $21.24 per share. 34,047
01/17/2023 Thomas P. Kelly
Chief Financial Officer 		2,403   Disposition at $21.24 per share. 51,039
01/17/2023 Jama Pitman
See Remarks 		1,603   Disposition at $21.24 per share. 34,047
10/03/2022 Matthew L. Sherman
EVP & Chief Medical Officer 		2,587   Disposition at $18.73 per share. 48,454
06/16/2022 Daniel L. Flynn
Chief Scientific Officer 		1,768   Disposition at $10.75 per share. 19,006
06/16/2022 Matthew L. Sherman
EVP & Chief Medical Officer 		1,768   Disposition at $10.75 per share. 19,006
06/16/2022 Daniel C. Martin
Chief Commercial Officer 		1,311   Disposition at $10.75 per share. 14,093
06/16/2022 Thomas P. Kelly
Chief Financial Officer 		1,768   Disposition at $10.75 per share. 19,006
06/16/2022 Jama Pitman
See Remarks 		1,298   Disposition at $10.75 per share. 13,953
04/29/2022 Brightstar Associates LLC
1,478,978   Acquisition at $10 per share. 14,789,780
03/21/2022 Steven L. Hoerter
President and CEO; Director 		3,150   Derivative/Non-derivative trans. at $9.11 per share. 28,696
02/16/2022 Daniel L. Flynn
Chief Scientific Officer 		1,366   Disposition at $9.05 per share. 12,362
02/16/2022 Matthew L. Sherman
EVP & Chief Medical Officer 		984   Disposition at $9.05 per share. 8,905
02/16/2022 Daniel C. Martin
Chief Commercial Officer 		1,146   Disposition at $9.05 per share. 10,371
02/16/2022 Thomas P. Kelly
Chief Financial Officer 		1,368   Disposition at $9.05 per share. 12,380
02/16/2022 Jama Pitman
See Remarks 		1,146   Disposition at $9.05 per share. 10,371
01/18/2022 Daniel L. Flynn
Chief Scientific Officer 		20,500   Award at $0 per share. 0
01/18/2022 Matthew L. Sherman
EVP & Chief Medical Officer 		20,500   Award at $0 per share. 0
01/18/2022 Daniel C. Martin
Chief Commercial Officer 		13,667   Award at $0 per share. 0
01/18/2022 Thomas P. Kelly
Chief Financial Officer 		20,500   Award at $0 per share. 0
01/18/2022 Jama Pitman
See Remarks 		13,667   Award at $0 per share. 0
12/15/2021 Daniel L. Flynn
Chief Scientific Officer 		11,100   Award at $0 per share. 0
12/15/2021 Matthew L. Sherman
EVP & Chief Medical Officer 		11,100   Award at $0 per share. 0
12/15/2021 Daniel C. Martin
Chief Commercial Officer 		8,300   Award at $0 per share. 0
12/15/2021 Thomas P. Kelly
Chief Financial Officer 		11,100   Award at $0 per share. 0
12/15/2021 Jama Pitman
See Remarks 		8,300   Award at $0 per share. 0
10/04/2021 Matthew L. Sherman
EVP & Chief Medical Officer 		2,659   Disposition at $33.17 per share. 88,199
05/03/2021 Michael D. Taylor
Director 		300   Disposition at $46.75 per share. 14,025
05/03/2021 Michael D. Taylor
Director 		7,700   Disposition at $46.07 per share. 354,739
05/03/2021 Michael D. Taylor
Director 		5,646   Derivative/Non-derivative trans. at $3.95 per share. 22,301
05/03/2021 Michael D. Taylor
Director 		2,354   Derivative/Non-derivative trans. at $1.89 per share. 4,449
/news/latest/company/us/dcph

MarketWatch News on DCPH

  2. Deciphera Pharmaceuticals stock price target raised to $18 from $11 at Stifel Nicolaus

    5:36 a.m. Sept. 27, 2022

    - Tomi Kilgore

  3. Deciphera Pharmaceuticals downgraded to hold from buy at Truist

    8:04 a.m. Nov. 8, 2021

    - Tomi Kilgore

  4. Deciphera Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    7:58 a.m. Nov. 8, 2021

    - Tomi Kilgore

  5. Deciphera Pharmaceuticals stock price target cut to $65 from $84 at Truist

    6:16 a.m. Oct. 4, 2021

    - Tomi Kilgore

  6. Deciphera Pharmaceuticals coverage resumed at Stifel with buy stock rating and $60 target price

    6:05 a.m. Sept. 30, 2021

    - Tonya Garcia

  7. Deciphera Pharmaceuticals started at buy with $75 stock price target at Stifel Nicolaus

    9:16 a.m. Dec. 3, 2020

    - Tomi Kilgore

  8. Callon, Fitbit, Genco Shipping, and Other 13D Filings

    9:30 p.m. Nov. 22, 2019

    - Barron's Online

  9. Deciphera Pharmaceuticals stock price target raised to $60 from $45 at SunTrust RH

    7:40 a.m. Aug. 14, 2019

    - Tomi Kilgore

  11. Deciphera Pharmaceuticals stock rockets 126% premarket after positive trial data for GIST treatment

    7:32 a.m. Aug. 13, 2019

    - Tomi Kilgore

  12. Deciphera Pharmaceuticals started at buy with $42 stock price target at Deutsche Bank

    1:17 p.m. July 18, 2019

    - Tomi Kilgore

  13. Deciphera Pharmaceuticals started at outperform with $47 stock price target at Raymond James

    7:25 a.m. Aug. 29, 2018

    - Tomi Kilgore

  14. Deciphera Pharmaceuticals started at buy with $60 stock price target at SunTrust RH

    6:54 a.m. July 5, 2018

    - Tomi Kilgore

  15. Deciphera Pharmaceuticals started at overweight with $30 stock price target at J.P. Morgan

    6:40 a.m. Oct. 23, 2017

    - Tomi Kilgore

/news/nonmarketwatch/company/us/dcph

Other News on DCPH

  5. 10-Q: DECIPHERA PHARMACEUTICALS, INC.

    6:12 a.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

    10:10 a.m. Oct. 5, 2022

    - Zacks.com

  10. Deciphera Pharmaceuticals (DCPH) Presents at ESMO Congress 2022

    2:35 p.m. Sept. 16, 2022

    - Seeking Alpha

  19. BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

    6:31 a.m. Aug. 4, 2022

    - Zacks.com

  20. Deciphera Pharmaceuticals Q2 2022 Earnings Preview

    1:29 p.m. Aug. 3, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Deciphera Pharmaceuticals, Inc.

200 Smith Street

Waltham, Massachusetts 02451

Phone

1 7812096400

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$96.15M

Net Income

$-299.96M

Employees

280.00

Annual Report for DCPH

/news/pressrelease/company/us/dcph

Press Releases on DCPH

  21. Loading more headlines...
Link to MarketWatch's Slice.